Moderna, Inc. Deferred Revenue Recognized
Moderna, Inc. (MRNA) reported Deferred Revenue Recognized of $76.00 million for the 3-month period ending 2022-09-30, per its 10-K filed 2024-02-23.
Discontinued › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2024-02-23
- Moderna, Inc. contract with customer, liability, revenue recognized for the quarter ending 2022-09-30 was $76.00M.
- Moderna, Inc. contract with customer, liability, revenue recognized for the quarter ending 2020-03-31 was $6.30M, a 53.59% decline year-over-year.
- Moderna, Inc. contract with customer, liability, revenue recognized for the quarter ending 2019-09-30 was $15.08M.
- Moderna, Inc. contract with customer, liability, revenue recognized for the quarter ending 2019-06-30 was $11.58M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month | Contract with Customer, Liability, Revenue Recognized 12 month as first filed |
|---|---|---|---|---|---|
| 2022-09-30 | $76.00M 10-K · filed 2024-02-23 | ||||
| 2020-03-31 | $6.30M 10-Q · filed 2020-05-07 | ||||
| 2019-12-31 | $1.26M 10-Q · filed 2020-05-07 | $51.99M 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $15.08M 10-Q · filed 2019-11-06 | $40.24M 10-Q · filed 2019-11-06 | |||
| 2019-06-30 | $11.58M 10-Q · filed 2019-08-08 | $25.16M 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $13.58M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |